Related Experiment Video

Updated: Jul 15, 2026

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
09:47

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery

Published on: June 2, 2022

A case series of xylometazoline overdose in children

Agnes G van Velzen1, Antoinette J H P van Riel, Claudine Hunault

  • 1National Poisons Information Centre, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. agnes.van.velzen@RIVM.nl

Clinical Toxicology (Philadelphia, Pa.)
|April 25, 2007
PubMed

Insights

Xylometazoline overdose in children rarely causes severe symptoms below 0.4 mg/kg. Hospital observation is often unnecessary for asymptomatic children with low-dose xylometazoline exposure.

Area of Science:

  • Toxicology
  • Pediatric Emergency Medicine

Background:

  • Imidazoline ingestions can cause serious toxicity even at low doses.
  • Current guidelines often recommend hospital observation for children with xylometazoline exposure, regardless of dose.
  • This study aimed to define a threshold dose below which hospitalization is not required.

Observation:

  • A prospective study collected data on 101 children under 6 years old with xylometazoline exposure.
  • Follow-up information was obtained for 63 cases.
  • Systemic doses were calculated, and symptom severity was monitored.

Findings:

  • No severe symptoms were observed in children exposed to xylometazoline doses below 0.4 mg/kg.
  • The upper limit of the 95% confidence interval for developing severe symptoms at doses below 0.4 mg/kg was 6%.

Implications:

  • A dose of 0.4 mg/kg may be a safe threshold for xylometazoline exposure in children.
  • This finding could help refine clinical guidelines for managing pediatric xylometazoline ingestions.
  • It may reduce unnecessary hospitalizations and associated healthcare costs.
Abstract

Related Concept Videos

Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...